Ironwood Pharmaceuticals Stock
Ironwood Pharmaceuticals Stock
A loss of -2.670% shows a downward development for Ironwood Pharmaceuticals.
So far the community has only identified positive things for Ironwood Pharmaceuticals stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Ironwood Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ironwood Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals | -2.670% | 19.737% | 25.517% | 427.536% | 36.842% | -63.417% | -57.919% |
| Ligand Pharmaceuticals | 1.570% | 8.571% | 3.825% | 106.522% | 14.458% | 190.076% | 55.993% |
| United Therapeutics | 0.710% | 0.305% | 6.071% | 96.765% | 15.305% | 136.647% | 188.129% |
| Ionis Pharmaceuticals Inc. | 0.740% | 1.307% | 4.427% | 158.641% | -4.208% | 93.462% | 90.073% |
Comments
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Show more
Ratings data for IRWD provided by MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for IRWD provided by MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Craig Hallum from $10.00 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IRWD provided by MarketBeat